key: cord-0956467-pme1llph authors: Veyrenche, N.; Bollore, K.; Pisoni, A.; Bedin, A.-S.; Mondain, A.-M.; Ducos, J.; Segondy, M.; Montes, B.; Pastor, P.; Morquin, D.; Makinson, A.; Le Moing, V.; Van De Perre, P.; Foulongne, V.; Tuaillon, E. title: Diagnosis value of SARS-CoV-2 antigen/antibody combined testing using rapid diagnostic tests at hospital admission date: 2020-09-22 journal: nan DOI: 10.1101/2020.09.19.20197855 sha: 950be9e61705b5b0f82fc47e1e560f84d6716454 doc_id: 956467 cord_uid: pme1llph Objectives: The implementation of rapid diagnostic tests (RDTs) may enhance the efficiency of SARS-CoV-2 testing, as RDTs are widely accessible and easy to use. The aim of this study was to evaluate the performance of a diagnosis strategy based on a combination of antigen and IgM/IgG serological RDTs. Methods: Plasma and nasopharyngeal samples were collected between 14 March and 11 April 2020 at hospital admission from 45 patients with RT-PCR confirmed COVID-19 and 20 negative controls. SARS-CoV-2 antigen (Ag) was assessed in nasopharyngeal swabs using the Coris Respi-Strip. For IgM/IgG detection, SureScreen Diagnostics and Szybio Biotech RDTs were used in addition to laboratory assays (Abbott Alinity i SARS-CoV-2 IgG and Theradiag COVID-19 IgM ELISA). Results: Using the Ag RDT, 13 out of 45 (29.0%) specimens tested positive, the sensitivity was 87.0% for Cycle Threshold (CT) values [≤] 25 and 0% for CT values > 25. IgG detection was associated with high CT values and the amount of time after the onset of symptoms. The profile of isolated IgM on RDTs was more frequently observed during the first and second week after the onset of symptoms. The combination of Ag and IgM/IgG RDTs enabled the detection of up to 84.0% of COVID-19 confirmed cases at hospital admission. Conclusion: Antigen and antibody-based RDTs showed suboptimal performances when used alone. However when used in combination, they are able to identify most COVID-19 patients admitted in an emergency department. Reported for the first time in December 2019, COVID-19 has become a major public health concern worldwide. Currently, clinical management of COVID-19 is mainly based on the prevention of transmission, viral tests, and supportive care. Wide access to SARS-CoV-2 testing is one of the keys to protecting populations. To be efficient, diagnostic assays must be accessible in different settings, ranging from the hospital to the community level, and from low to high incomes countries 1 . Reverse transcriptase polymerase chain reaction (RT-PCR) for the detection of SARS-CoV-2 RNA in upper and lower respiratory tract specimens (nasopharyngeal swab, throat swab, and sputum) is the gold standard to confirm COVID-19 2 . RT-PCR tests have an overall sensitivity estimated around 70.0% in nasopharyngeal sampling 3 with a high specificity. RT-PCR is ideal for the diagnosis of COVID-19 during the first week after the onset of symptoms because the viral load is high during this period. Beyond day 14, when the viral load is low or undetectable, the performance of RT-PCR diminishes 4 . In such situations, serological tests may help to confirm a COVID-19 diagnosis in individuals with a high clinical suspicion but who tested negative for SARS-CoV-2 RNA. Both nucleic acid tests and automated serological tests require sample collection, transportation, and laboratory analysis, leading to a delayed response and limiting the efficiency of SARS-CoV-2 testing strategies. Furthermore, insufficient access to nearby laboratory facilities is a major concern in intermediate and low-income countries. A diagnostic test is characterized not only by its analytical performance, mainly estimated by sensitivity (Se) and specificity (Sp) but also by its overall accessibility 5 . The implementation of rapid diagnostic tests (RDTs) in the diagnosis of COVID-19 could have significant benefits by enhancing the efficiency of large testing strategies 6 . RTDs are useful devices that facilitate testing outside of laboratory settings, a capability needed for hard to reach populations 7 . In addition, RTDs deliver results in a shorter amount of time than RT-PCR. This time saving is important for the identification, isolation and provision of appropriate clinical care to patients with COVID-19. RTDs also reduce overloads in emergency departments 8 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 4 COVID- 19 RDTs are based on the detection of either SARS-CoV-2 antigen in respiratory specimens or anti-SARS-CoV-2 antibodies in whole blood or plasma/serum. Experience with RDTs used to detect antigens from other respiratory viruses in respiratory samples suggests that the sensitivity of these tests is lower than that of nucleic acid tests, ranging from 34.0% to 80.0% 9 . Recent publications have confirmed that COVID-19 RDTs are considerably less sensitive than molecular tests, and may therefore generate false negative results 10 . Antigen detection is mainly dependant on the viral concentration, hence most specimens with high viral concentrations test positive for antigen 11 12 13 . In contrast to RDTs based on Ag detection, RDTs that detects anti-SARS-CoV-2 antibodies are widely available, and a very large number have been approved by the FDA and CE. Although weak or absent humoral responses have been reported, especially in mild and moderate forms of COVID-19, most patients develops an antibody response within the first two weeks of COVID-19 14 15 16 . Serologic assays also can be useful in conjunction with molecular assays for the clinical assessment of persons who present themselves for testing long after the onset of symptoms. While RDTs might constitute a simple screening method, they have shown limitations in the early phase of acute infections due to the time required for an antibody response. Consequently, COVID-19 diagnosis based on IgM and IgG detection is often delayed to the second phase of the disease, when some opportunities for therapy and prevention of SARS-CoV-2 transmission already have been lost. Due to the overall performance of the tests, WHO and FDA do not recommend the use of Ag or antibody-detecting RDTs as the sole basis for the diagnosis of infection, but are encouraging research studies to establish their usefulness. Diagnostic algorithms based on Ag plus antibodies detection using RDTs need to be compared to the molecular techniques which currently are the gold standard for COVID-19 diagnosis 7 . The aim of this study was to evaluate the performance of a combination of antigen and serological RDTs to diagnose COVID-19 in hospitalized patients who tested positive for SARS-CoV-2 RNA using RT-PCR. . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . Plasma samples were tested using the SARS-CoV-2 IgG immunoassay on the Alinity i system (Abbott, Illinois, USA). The SARS-CoV-2 assay is a chemiluminescent microparticule immunoassay (CMIA) intended for the qualitative detection of SARS-CoV-2 nucleoprotein IgG. The cut-off value for a positive result was defined by the manufacturer's instructions: a ratio < 1.4 calculated index (S/C) is considered negative and a ratio ≥ 1.4 is considered positive. Anti-SARS-CoV-2 IgM were not assessed by the Alinity i platform since the assay was not available at the time of the study. IgM directed against SARS-CoV-2 protein S were detected using the ELISA COVID-19 THERA02 IgM assays (Theradiag, Marne la Vallée, France). The IgM positive cut-off is ratio ≥1. All tests were performed according to the manufacturer's instructions. The Coris COVID-19 Ag Respi-Strip (BioConcept®, Gembloux, Belgium), was used to test Ag is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . 7 visible in the IgM and/or IgG position at 15 minutes on the test line, even a weak one, must be interpreted as positive. The experimental data were summarized by number and percentage for categorical variable, CT values were compared with the amount of time following the onset of symptoms. The two parameters were moderately correlated (R 2 = 0.3151, Fig.1 ). The presence of anti-SARS-CoV-2 IgM and IgG was retrospectively assessed on plasma samples collected at admission in the emergency department using anti-SARS-CoV-2 IgG CMIA and IgM ELISA (Sup. Tables. S1. A and B). A total of 24 out of 45 COVID-19 confirmed patients tested positive for IgG using the Abbott assay, resulting in a sensitivity (95% CI) of 53.3% (38.8 -67.9) (Sup. Tables. S1. A and B). All but one patient tested two weeks after the onset of symptoms tested positive for IgG using the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . Nasopharyngeal and plasma samples then were tested for SARS-CoV-2 Ag and IgM/IgG using RDTs. All results of antigen and serologic RDTs were considered valid based on a visible control band, although the intensity of the band was weak for some specimens. Clinical samples collected from COVID-19 negative patients were used to assess the specificities of the RDTs. All controls samples tested negative for SARS-CoV-2 antigen and antibodies regardless of the assay (specificity=100.0%). Among 45 nasopharyngeal samples collected in confirmed Covid-19 patients, 13 specimens tested positive using the Ag RDT, resulting in a sensitivity (95% CI) of 29.0% (15.7 -42.3) ( Fig.1 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Seventeen samples tested positive for IgM but negative for IgG using the serology RDTs. Among these samples, IgM were also detected by ELISA in 11 out of 17 cases (Sup. Fig S4. B). RT-PCR CT values were higher in patients who tested positive using the SureScreen IgM is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.19.20197855 doi: medRxiv preprint sensitivity of 80.0% (68.3 -91.7) (Fig. 6) . The combination of RDTs based on Ag plus IgM detection significantly improved the identification of COVID-19 cases at hospital admission compared to the Coris Ag RDT alone (p<0.0001) or the IgM/IgG RDTs alone (p=0.0113 and p=0.0142, respectively, Fig. 6 ). In this study, we observed that a majority of nasopharyngeal samples with high concentrations is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . Coris RDT can detect the virus before the development of a serological response, and Ag tests might have some advantages when used as a triage test in a pandemic context. First, Ag testing is simple and can be performed in about 15 minutes after the collection of samples. Secondly, the Coris Ag RDT that targets the SARS-CoV and SARS-CoV-2 highly conserved nucleoprotein antigen does not cross-react with seasonal coronaviruses 11 . Hence, the specificity of the assay appears close to 100% in all published studies 13 12 11 . Thanks to its high specificity and positive predictive value, a positive result using the Coris RDT would make it possible to avoid or delay the RT-PCR test 11 . The two serological RDTs evaluated in this study also showed a high specificity but a variable sensitivity according to antibody isotype, time from onset of symptoms and RT-PCR CT values. The performances of the RDTs to detect IgG was lower than that of the Abbott SARS-CoV-2 IgG assay. While these RDTs had a lower capacity to detect low IgG concentrations compared to the chemiluminescence immunoassay, both the SureScreen RDT and the Szybio RDT had a good capacity to detect IgM (Sup. Figures S4. A and B) . Results of previous studies suggest that the performances of immunoassays to detect IgM in the early phase of infection varies considerably according to the methods used. The detection of anti-SARS-CoV-2 IgM have been observed several days before the detection of IgG 21 22 , but others studies reported IgM seroconversion at the same time or after IgG 23 24 25 26 27 . It has been established that during the B cell response, IgM cells are present before IgG class switching. However, during the course of COVID-19 infection, the peak of IgM may be low and delayed compared to that of IgG. Data from a recent study comparing RDTs confirm that the analytical sensitivity for IgM is highly variable depending on the assay whereas the detection of IgG is more homogeneous 28 , hence early IgM detection is strongly dependent on the test used. Beside detection of seroconversion in the early phase of infection, assessment of SARS-CoV-2 IgM may be of interest to distinguish between a recent versus a later immunization since most COVID-19 cases become seronegative for IgM within two months after symptom onset 29 . The overall efficiency of diagnostic strategies is not only characterized by the intrinsic performances of in vitro assays, which are mainly estimated through sensitivity and specificity, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . but also by their accessibility 8 , effectiveness, speed of process, and period of time to obtain results. Furthermore, diagnosis can benefit from a testing algorithm based on successive steps of triage, screening, and confirmation. Tests performed at the point-of-care offer interesting benefits, including rapid diagnosis and simplicity of use outside of laboratory facilities 18 . Our results have shown that a combination of antigen and antibodies-based RDTs is highly specific and detects most carriers of SARS-CoV-2 admitted to the hospital at different times over the course of the COVID-19 infection. A synthetic representation of variation over time in biological markers for COVID-19 diagnosis is proposed in Figure 7 . In conclusion, our results show that the Coris Ag immunochromatographic assay has insufficient sensitivity for the diagnosis of COVID-19 when used alone, but it could be a valuable tool when used in an integrative diagnostic strategy. Ag and IgM/IgG rapid diagnosis assays are complementary, and when used in combination are able to identify most patients with COVID-19 admitted in an emergency department. To be an effective alternative to nucleic acid tests and have a significant place in the global response to the COVID-19 pandemic, RDTs must combine high sensitivity to detect SARS-CoV-2 antigens and early and specific detection of IgM. We thank Grace Delobel for English language editing and review services. University (MUSE). The authors declare that there are no conflicts of interest. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.19.20197855 doi: medRxiv preprint Audio Interview: New Research on Possible Treatments for Covid-19 Interpreting Diagnostic Tests for SARS-CoV-2 Kesselheim Aaron S. False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications Virological assessment of hospitalized patients with COVID-2019 Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C EasyCOV : LAMP based rapid detection of SARS-CoV-2 in saliva Advice on the use of point-of-care immunodiagnostic tests for COVID-19: scientific brief COVID-19 infection: the perspectives on immune responses Rapid Tests for Influenza, Respiratory Syncytial Virus, and Other Respiratory Viruses: A Systematic Review and Meta-analysis Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19 Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs Multiplex detection and dynamics of IgG antibodies to SARS-CoV2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients Antibody tests for identification of current and past infection with SARS-CoV-2 Clinical management of COVID-19 Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Predicting infectious SARS-CoV-2 from diagnostic samples Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Antibody Detection and Dynamic Characteristics in Patients With Coronavirus Disease Profile of specific antibodies to SARS-CoV-2: The first report Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients Dynamics and significance of the antibody response to SARS-CoV-2 infection